Batu Biologics Recruits Cancer Immunologist to Scientific Advisory Board

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immunotherapy company working to develop ValloVax, an anti-angiogenic cancer vaccine, announced today the addition of Dr. Deyu Fang to its Scientific Advisory Board. Deyu Fang, Ph.D. is an immunologist and associate professor working in the Department of Pathology at Northwestern University Feinberg School of Medicine.

"Expanding our academic collaborations is a major focus here at Batu Biologics," stated Samuel C. Wagner, President and CEO of Batu Biologics. "Dr. Fang will provide additional channels of collaboration and his expertise will be essential as we conduct additional preclinical experimentation to validate the clinical potential of ValloVax."

Dr. Fang will provide Batu Biologics oversight in the development of ValloVax™, assisting in the design and implementation of IND-enabling experiments. He has several lung cancer mouse models that can be used to quantify the anti-tumor activity of ValloVax™.

Dr. Fang has won several awards throughout his research career, including NIH Type 1 Diabetes Pathfinder Award and the AAI (American Association of Immunologist) Young Investigator Travel Award. Dr. Fang is a recipient of over 12 of NIH grants since 2009 to present. With the current active three being RO1 NIH, his research focuses on T cell activation, immune tolerance, and autoimmunity.

About Batu Biologics:

Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the "Achilles Heel of Cancer": the tumor blood vessels. Batu's flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics plans to file an Investigational New Drug (IND) application for ValloVax in Q1 of 2015, seeking clinical approval to treat patients with lung cancer.


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.